SGD Pharma to Introduce Siliconized Molded Glass Vials at CPHI Milan to Showcase Sustainable Packaging

Cagkan - stock.adobe.com

On Oct. 1, 2024, SGD Pharma, a global provider of pharmaceutical glass packaging solutions, announced that it plans to exhibit an innovative range of products and services at CPHI Milan in Milan, Italy, from Oct. 8–10. As part of its exhibition, the company will introduce its siliconized molded glass vials. The company’s siliconization process is an internal treatment that provides additional functionalities to a glass vial, according to a company press release.

The internal silicon coating provides protection for sensitive, aggressive, and viscous drug products. In doing so, the coating reduces interactionwiththepackagingandpreservesdrugproductintegrity, according to the press release. SGD stated in the release that siliconizationisavailable for all glass types and for vials ranging in size from 3 mL to 500 mL, both clear and amber glass. The siliconization processissuited toallroutesofadministration, including parenteral,oral, andnasal administration.

“SGDPharma’s €5 million [US$5.5 million] investment in the siliconization production line at its state-of-the-art Saint-Quentin Lamotte(SQLM)plant [in France]enablescustomerstoreceiveordersofhigh-performancevialsatspeed meeting global demand,” the company stated in its press release.

The growing demand for the approval of biologics as well as new therapeutic approaches and the development of specialty drugs is driving the need for ready-to-use (RTU) packaging, SGD Pharma said in its press release. The company offers a RTU solution in molded glass, which includes its Sterinity EZ-fillvials (aregisteredtrademarkofStevanatoGroupand/oritsaffiliatesinoneormorejurisdictions). The Sterinity EZ-fillvials are designed for the rigorous requirements demanded by the pharmaceutical industry. The increased quality and flexibility of these vials enable the shortening of time-to-market and reduce total cost of ownership, according to the press release. Sterinity is suitable for various applications in veterinary and human health.

“AtCPHI2024,weareshowcasingsolutions developedwithourpharmaandveterinarycustomers’needsinmind,aimedatenablingthem tobringtheirdrugstomarketquicklyandsafely.Thiscommitmenttoinnovationisreflectedby our dedication to sustainability, which is an integral component of our company strategy. As we support theUNGlobalCompact forthefifthconsecutiveyear, we are particularlyproudof our progress in reducing carbon emissions at our global glass manufacturing sites,” said OlivierRousseau,CEO,SGDPharma,in the release. “SGD Pharma’s renewable energy initiatives, including the upgrade of our furnace at Saint Quentin Lamotte (SQLM) in France and the installation of solar panels at our Vemula, India, plant, underscore an overarching focus on decarbonization with the company-wide goal to cut emissions recorded in 2020, by 35% by 2030, and by 65% by 2040. These efforts reflect our responsibility to our customers, partners and the planet as we strive for a safer and healthier environment.”

The company will present an extension to its Sterinity range at CPHI, including the debut of aRTUTypeIImoldedglassvial. Sterinity RTU in Type II is expected to initially be available in size 10H, and an extendedrangeofsizes is expectedto launch during2025. SterinityTypeIiscurrently available in sizes 10 mL, 20 mL, 25 mL, 50 mL, and 100 mL. Type I is available in both clear and amber glass.

In addition, SGD Pharma will present an extension to its IDENCY range that includes 20 mL and 6 mL sizes. The company will also introduce new caps for its Ensiemo syrup bottles. The presentation will include the following:

IDENCY, a Type I glass vial that combines the benefits of both molded and tubular technologies, for parenteral sensitive drugs.

Ensiemofull packaging solution, apharma-grade TypeIII glass vialand pipette, which is now available with polypropylene or polyethylene caps for a tamper evident and child resistant closure.

The company now offers LabServices, an analytical testing service in molded glass for its customersandpartners (1). Through this service, experts at SGD Pharma’s SQLM plant provide analytical testing for pharma and biopharma companies, contract manufacturing organization and contract development and manufacturing organizations, and other glass manufacturers. The company expects to launch more LabServices in 2025.

The showcase will be held at SGD Pharma’s booth, 20B11, during CPHI.

Reference

1. SGD Pharma. New Labservices for Pharmaceutical Molded and Tubular Glass, Available Exclusively to SGD Pharma Customers and Partners. sgd-pharma.com/labservices (accessed Oct. 2, 2024).

Source: SGD Pharma